viive

A/Prof Viive Howell is the Research Director of the Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney at Royal North Shore Hospital and the Director of Pre-clinical Research for the Sydney Neuro-Oncology Group.

She is also the Co-Leader of Inflammation in Cancer Flagship and Leader of the Immunotherapy Pillar for Sydney Vital. Her team’s research focuses on overcoming resistance to current cancer agents, the development of improved treatment strategies and identification of novel therapeutic targets. This research is ongoing in number of cancers including brain cancer, lung cancer, mesothelioma, colorectal cancer, pancreatic cancer and ovarian cancer.

Her PhD studies (2002 – 2004) led directly to improvements in the diagnosis of parathyroid cancer and papers arising from this work have been cited over 150 times. Since completing her PhD in 2005, she has been awarded $5 million in research funding for project grants, fellowships and equipment and infrastructure.

Research Interests

Viive’s research expertise is in the areas of genetics (molecular, cancer and mouse) in vivo modelling and biomarker discovery. Her major focus is translating basic science research findings to improvements in clinical diagnosis. Primarily, her research focuses on ovarian cancer with the aim of improving understanding of the causes and progression of the disease and identifying new biomarkers which may facilitate earlier diagnosis.

To study the interplay of hormonal, genetic and other factors leading to ovarian cancer, Howell is currently developing new genetic mouse models and in addition, is undertaking in vitro studies to discover novel regulators of pathways that are involved in cancer development.

Project Grants

Ramsay Research and Teaching Knowledge Discovery research grant” Exploring a novel nanotechnology strategy for the neo-adjuvant treatment of rectal cancer by photodynamic therapy and radiotherapy”

Ramsay Health Care 2017

Colorectal Surgical Society of Australia and New Zealand Foundation research grant “Exploring a novel nanotechnology strategy for the neo-adjuvant treatment of rectal cancer by photodynamic therapy and ionising radiation”

Colorectal Surgical Society of Australia and New Zealand Foundation 2017

Sydney Neuro-Oncology Group research grant “Investigating Inflammation and Coagulation in Brain Cancer

Sydney Neuro-Oncology Group 2017

Avner Pancreatic Cancer Foundation ”Woolies on Wheels” Innovation Grant, Treating pancreatic cancer with FXYD3 peptide analogues”

Avner Pancreatic Cancer Foundation 2017

Lambert Initiative of Cannabinoid Therapeutics grant “Improved treatment for mesothelioma: Can cannabinoids address this unmet need?”

Lambert Initiative of Cannabinoid Therapeutics 2016

Sydney Vital seed grant “Assessment of Tumour-Educated Platelets (TEPs) for monitoring therapy resistance and recurrence of brain tumours”

Sydney Vital 2016

Cure Brain Cancer Grant: “Stage 1 in the development of immunotherapies for high grade glioma: pilot project”

Cure Brain Cancer 2016

Mark Hughes Foundation grant “Laying the foundations for improved treatments for IDH-mutated glioma”

Mark Hughes Foundation 2016

Avner Pancreatic Cancer Foundation ”Woolies on Wheels” Innovation Grant; “Harnessing the power within to conquer pancreatic cancer”

Avner Pancreatic Cancer Foundation 2016

Ramsay Research & Teaching Committee Knowledge Discovery grant (Biomedical Research): “Personalising treatment for brain cancer”

Ramsay Health Care 2015

Sydney Vital Pillar 2 funding as lead Investigator

Sydney Vital 2015

Ramsay Research & Teaching Committee Clinical Development grant: “Routine application of next generation sequencing for identifying Actionable mutations in patients with non‐small cell lung cancer using small tissue biopsies, with comparison to liquid biopsies for enabling rapid access to personalised treatment pathways‐ a pilot feasibility study”

Ramsay Health Care 2014

NTCRU Seed Funding Grant “Seeking Inflammatory and Genetic Based Prognostic Markers in Colorectal Cancer”

Northern Translational Cancer Research Unit 2013

Ovarian Cancer Research Foundation project grant “Serum microRNAs as predictive tools for optimal cytoreduction in women with serous epithelial ovarian cancer”

Ovarian Cancer Research Foundation 2013

Rebecca L Cooper Medical Research Foundation Award to fund a PhD scholar for Genetics Research

Rebecca L Cooper Medical Research Foundation 2013

Ovarian Cancer Research

Northern Sydney Local Health District

Cure Cancer Foundation Australia, “A random mutagenesis strategy for identification of new targets for the treatment of malignant melanoma”

Northern Sydney Local Health District 2012

Cancer Council NSW Project Grant: “New opportunities for the study of ovarian cancer through characterisation of mouse models”

Cancer Council 2011

NHMRC Project Grant: “FSH control of ovarian function”

National Health and Medical Research Council 2011

Royal North Shore Hospital Staff Specialist Trust Fund Early Career Research Grant: “Identification of novel genes that regulate tumour angiogenesis”

Royal North Shore Hospital 2010

University of Sydney Cancer Research Fund Grant: “Relationships between miRNA and the PI3K/mTOR pathway in ovarian cancer”

University of Sydney 2009

Cure Cancer Australia Foundation Grant: “Ovarian surface epithelial carcinoma modelling”

Cure Cancer Australia 2008

Faculty of Medicine, University of Sydney, Early Career Researcher Grant: “Testing the gonadotropin theory of ovarian surface epithelial carcinoma development in Brca1-deficient mice”

University of Sydney 2008

Northern Sydney Central Coast Area Health Service, New Researcher Grant: “A forward genetic approach to identify primary tumorigenic events in mouse ovarian tumours with and without loss of Brca1”

Northern Sydney Central Coast Area Health Service 2008

 

Equipment Grants

The University of Sydney and NHMRC Equipment Grant 2017: Vevo 3100 Preclinical Imaging Platform

University of Sydney and National Health and Medical Research Council 2017

Cancer Institute NSW Research Equipment Grant Scheme: “ZOOMing in on new cancer therapies: Real-time quantitative live cell imaging for cancer research and drug discovery”

Cancer Institute NSW 2017

Cancer Institute NSW Research Equipment Grant Scheme: “Translational Cancer Research Facility for Pre-clinical image-guided focal radiotherapy”

Cancer Institute NSW 2016

Cancer Institute NSW Research Equipment Grant Scheme: “Streamlining specimen preparation for researchers from samples stored in biobanks”

Cancer Institute NSW 2015

NHMRC University of Sydney Equipment Grant Scheme 2015: “Qseq automated personal DNA sequencer”

National Health and Medical Research Council 2015

NHMRC University of Sydney Combined Equipment Grant Scheme: “A high-throughput, bright-field and fluorescence digital slide scanning platform and service that is both research- and teaching-focused and available University-wide.”

National Health and Medical Research Council 2013

Rebecca L Cooper Medical Research Foundation: “Towards personalising chemotherapeutic treatment for cancer – investigating inter-ethnic differences in genetic susceptibility to anti-cancer drug toxicity”

Rebecca L Cooper Medical Research Foundation 2013

Rebecca L Cooper Medical Research Foundation: “Scanning for mutations in cancer susceptibility genes”

Rebecca L Cooper Medical Research Foundation 2012

Ramaciotti Foundation Establishment and Equipment Grant, “Incucyte FLR Microscope System”

Ramaciotti Foundation 2011

University of Sydney NHMRC Equipment Grant: “IncuCyte FLR Microscope System”

University of Sydney 2011

Cancer Institute NSW Research Equipment Grant: “In-Vivo Multispectral Imaging FX System: small animal imaging for multi-modal molecular signal localisation in live animals”

Cancer Institute NSW 2010

Northern Sydney Area Cancer Key Area Grant: “Building capacity in the Kolling Genomics Core Facility – robotic liquid handling workstation for automated sample preparation”

Northern Sydney Area Cancer 2010

Royal North Shore Hospital Staff Specialist Trust Fund Equipment Grant: “Robotic liquid handling workstation for automated sample preparation –Building capacity in the Kolling Genomics Core Facility”

Royal North Shore Hospital 2010

University of Sydney Northern Clinical School Research Infrastructure: “Infrastructure support for the Kolling Institute Genomics Core and Confocal Microscopy Facility”

University of Sydney Northern Clinical School 2009

Northern Sydney Area Cancer Key Area Grant: “Building capacity in the Genomics Core”

Northern Sydney Area Cancer 2008

University of Sydney Northern Clinical School Research Infrastructure Block Grant Funding: “Real time instrumentation to enable PCR array profiling capabilities, high resolution melt analysis and more”

University of Sydney 2008

Year Award/ Honour Institution
2016 Cure Cancer Australia and CanToo Australian Community Researcher Award  Cure Cancer Australia and CanToo Australian Community Researcher
2015 Inaugural Cancer Immunotherapies conference, NY, USA Mar Hughes Foundation Hunter Medical Research Institute Travel Fellowship
2014 The International Mammalian Genome Conference, ME, USA Ramsay HealthCare and Royal North Shore Scientific Staff Council
2012 Northern Translational Cancer Research Unit Fellowship
2009 Best publication by a post-doctoral scientist (less than 5 years post-PhD) Kolling Institute Cancer Institute NSW Early Career Development Fellowship
2005 CJ Martin Overseas Biomedical Postdoctoral Research Fellowship National Health and Medical Research Council
2003 Research Travel Award – American Society for Human Genetics Meeting, CA, USA, 2003 Royal North Shore Beryl and Jack Jacobs
2002 Dora Lush Postgraduate Research Scholarship National Health and Medical Research Council
2002 Cancer Memorial Research Scholarship Royal North Shore Hospital
2002 Financial assistance for study at Van Andel Research Institute, USA Northern Sydney Health Ramsay HealthCare
2012 Northern Translational Cancer Research Unit Fellowship. “Experimental models for cancer gene discovery Northern Translational Cancer Research Unit
2009 Cancer Institute NSW Early Career Development Fellowship: “Ovarian cancer: Experimental models for understanding the molecular events important to this malignancy” Cancer Institute NSW
2005 NHMRC CJ Martin Overseas Biomedical Postdoctoral Research Fellowship, “Functional characterisation of the recently discovered mammalian genes, SCNM1 and HRPT2” National Health and Medical Research Council
2002 NHMRC Dora Lush Postgraduate Research Scholarship, “The Molecular Genetics of Hyperparathyroidism” National Health and Medical Research Council
2002 Royal North Shore Cancer Memorial Research Scholarship, “The Molecular Genetics of Hyperparathyroidism” Royal North Shore Hospital

Diakos, C., Charles (nee Slaviero), K., Chua, W., Howell, V., Clarke, S. (2015). Biomarkers in Metastatic Colorectal Cancer. In Victor R. Preedy and Vinood B. Patel (Eds.), Biomarkers in Cancer, (pp. 601-629). Dordrecht: Springer. [More Information]

Howell, V., Colvin, E. (2014). Genetically Engineered Insertional Mutagenesis in Mice to Model Cancer: Sleeping Beauty. In Shree Ram Singh, Vincenzo Coppola (Eds.), Mouse Genetics: Methods and Protocols, (pp. 367-383). New York: Springer. [More Information]

Marsh, D., Howell, V. (2010). The Use of Denaturing High Performance Liquid Chromatography (DHPLC) for Mutation Scanning of Hereditary Cancer Genes. In Michelle Webb (Eds.), Cancer Susceptibility: Methods and Protocols, (pp. 133-145). United States: Humana Press. [More Information]

Pham, B., Colvin, E., Pham, T., Kim, B., Fuller, E., Moon, E., Barbey, R., Yuen, S., Rickman, B., Bryce, N., Howell, V., Hawkett, B., et al (2018). Biodistribution and clearance of stable superparamagnetic maghemite iron oxide nanoparticles in mice following intraperitoneal administration. International Journal of Molecular Sciences, 19(1), 205. [More Information]

Vafaee, F., Colvin, E., Mok, S., Howell, V., Samimi, G. (2017). Functional prediction of long non-coding RNAs in ovarian cancer-Associated fibroblasts indicate a potential role in metastasis. Scientific Reports, 7(1), 1-11. [More Information]

Itchins, M., Chia, P., Hayes, S., Howell, V., Gill, A., Cooper, W., John, T., Mitchell, P., Millward, M., Clarke, S., Pavlakis, N., et al (2017). Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. Asia-Pacific Journal of Clinical Oncology, 13 Suppl 3, 3-13. [More Information]

Gonzales, N., Howell, V., Smith, C. (2016). 29th International Mammalian Genome Conference meeting report. Mammalian Genome, 27(5-6), 169-178. [More Information]

Hayes, S., Haefliger, S., Harris, B., Pavlakis, N., Clarke, S., Molloy, M., Howell, V. (2016). Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. Journal of Breath Research, 10(3), 1-26. [More Information]

Parker, N., Hudson, A., Khong, P., Parkinson, J., Dwight, T., Ikin, R., Zhu, Y., Cheng, Z., Vafaee, F., Chen, J., Wheeler, H., Howell, V. (2016). Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Scientific Reports, 6, 1-10. [More Information]

Moran-Jones, K., Gloss, B., Murali, R., Chang, D., Colvin, E., Jones, M., Yuen, S., Howell, V., Brown, L., Wong, C., et al (2015). Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 6(42), 44551-44562. [More Information]

Howell, V., Davidson, B. (2015). Editorial: Advances in epithelial ovarian cancer: model systems, microenvironmental influences,therapy, and origins. Frontiers in Oncology, 5, 1-3. [More Information]

Kan, C., Howell, V., Hahn, M., Marsh, D. (2015). Genomic Alterations as Mediators of miRNA Dysregulation in Ovarian Cancer. Genes Chromosomes and Cancer, 54(1), 1-19. [More Information]

Upton, D., Fuller, E., Colvin, E., Walters, K., Jimenez, M., Desai, R., Handelsman, D., Howell, V., Allan, C. (2015). Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors. Hormones and Cancer, 6(4), 142-152. [More Information]

Parker, N., Khong, P., Parkinson, J., Howell, V., Wheeler, H. (2015). Molecular heterogeneity in glioblastoma: potential clinical implications. Frontiers in Oncology, 5, 1-9. [More Information]

Weir, C., Hudson, A., Peters, L., Howell, V. (2015). Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model. Journal of Visualized Experiments, 104, 1-12. [More Information]

Jankova, L., Dent, O., Molloy, M., Chan, C., Chapuis, P., Howell, V., Clarke, S. (2015). Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. Proteomics – Clinical Applications, 9(11-12), 1078-1086. [More Information]

Cho, A., Howell, V., Colvin, E. (2015). The extracellular matrix in epithelial ovarian cancer – A piece of a puzzle. Frontiers in Oncology, 5, 1-16. [More Information]

Fuller, E., Howell, V. (2014). Culture Models to Define Key Mediators of Cancer Matrix Remodeling. Frontiers in Oncology, 4, 1-7. [More Information]

Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014). Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports, 4, 1-11. [More Information]

Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014). From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology, 27, 118-127. [More Information]

Howell, V. (2014). Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet? Seminars in Cell & Developmental Biology, 27, 106-117. [More Information]

Howell, V. (2014). Mice and men working together for over 100 years in the fight against cance. Seminars in Cell and Developmental Biology, 27, 52-53. [More Information]

Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014). Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research, 2(5), 469-479. [More Information]

Holt, D., Henthorn, P., Howell, V., Robinson, B., Benn, D. (2014). Succinate Dehydrogenase Subunit D and A Succinate Dehydrogenase Subunit B Mutation Analysis in Canine Phaeochromocytoma and Paraganglioma. Journal of Comparative Pathology, 151(1), 25-34. [More Information]

Parker, N., Correia, N., Crossley, B., Buckland, M., Howell, V., Wheeler, H. (2013). Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology, 6(6), 742-748. [More Information]

Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2013). Resistance to EGFR targeted antibodies – expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer, 28(1), 44-46. [More Information]

Tang, J., Carmichael, C., Shi, W., Metcalf, D., Ng, A., Hyland, C., Jenkins, N., Copeland, N., Howell, V., Zhao, Z., et al (2013). Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 110(15), 6091-6096. [More Information]

Kan, C., Hahn, M., Gard, G., Maidens, J., Huh, J., Marsh, D., Howell, V. (2012). Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer, 12, 1-9. [More Information]

Le, T., Mardini, M., Howell, V., Funder, J., Ashton, A., Mihailidou, A. (2012). Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension, 59(6), 1164-1169. [More Information]

Howell, V. (2012). Sleeping Beauty – a mouse model for all cancers? Cancer Letters, 317(1), 1-8. [More Information]

Hahn, M., Howell, V., Gill, A., Clarkson, A., Weaire-Buchanan, G., Robinson, B., Delbridge, L., Gimm, O., Schmitt, W., Teh, B., Marsh, D. (2010). CDC73/HRPT2 CpG island hypermethylation and mutation of 5′-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 17(1), 273-282. [More Information]

Howell, V., Gill, A., Clarkson, A., Nelson, A., Dunne, R., Delbridge, L., Robinson, B., Teh, B., Gimm, O., Marsh, D. (2009). Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. The Journal of Clinical Endocrinology and Metabolism, 94(2), 434-441. [More Information]

Howell, V., de Haan, G., Bergren, S., Jones, J., Culiat, C., Michaud, E., Frankel, W., Meisler, M. (2008). A targeted deleterious allele of the splicing factor SCNM1 in the mouse. Genetics, 180(3), 1419-1427. [More Information]

Howell, V., Jones, J., Bergren, S., Li, L., Billi, A., Avenarius, M., Meisler, M. (2007). Evidence for a direct role of the disease modifier SCNM1 in splicing. Human Molecular Genetics, 16(20), 2506-2516. [More Information]

Marsh, D., Hahn, M., Howell, V., Gill, A. (2007). Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opinion on Medical Diagnostics, 1(3), 377-392. [More Information]

Gill, A., Clarkson, A., Gimm, O., Keil, J., Dralle, H., Howell, V., Marsh, D. (2006). Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias. American Journal of Surgical Pathology, 30(9), 1140-1149. [More Information]

Gimm, O., Lorenz, K., Nguyen Thanh, P., Schneyer, U., Bloching, M., Howell, V., Marsh, D., Teh, B., Krause, U., Dralle, H. (2006). Prophylactic parathyroidectomy for familial parathyroid carcinoma. Chirurg, 77(1), 15-24. [More Information]

Howell, V., Cardinal, J., Richardson, A., Gimm, O., Robinson, B., Marsh, D. (2006). Rapid Mutation Screening for HRPT2 and MEN1 Mutations Associated with Familial and Sporadic Primary Hyperparathyroidism. Journal of molecular diagnostics, 8(5), 559-566. [More Information]

Howell, V., Zori, R., Stalker, H., Williams, C., Jesse, N., Nelson, A., Robinson, B., Marsh, D. (2004). A molecular diagnosis of hyperparathyroidism-Jaw tumor syndrome in an adolescent with recurrent kidney stones. The Journal of Pediatrics, 145(4), 567-567. [More Information]

Howell, V., Proos, A., La Rue, D., Jensen, C., Beach, F., Burnett, L. (2004). Carrier Screening For Canavan Disease In Australia. Journal of Inherited Metabolic Disease, 27(2), 289-290. [More Information]

Haven, C., Howell, V., Eilers, P., Dunne, R., Takahashi, M., Van Puijenbroek, M., Furge, K., Kievit, J., Tan, M., Fleuren, G., Robinson, B., Delbridge, L., Philips, J., Nelson, A., Marsh, D., et al (2004). Gene Expression Of Parathyroid Tumors: Molecular Subclassification And Identification Of The Potential Malignant Phenotype. Cancer Research, 64(20), 7405-7411. [More Information]

Teh, B., Howell, V., Haven, C., Kahnoski, K., Khoo, S., Petillo, D., Chen, J., Fleuren, G., Robinson, B., Delbridge, L., et al (2004). Human Gene Mutations – Gene Symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome. Human Genetics, 114(2), 221-224.

Barlow-Stewart, K., Burnett, L., Proos, A., Howell, V., Huq, F., Lazarus, R., Aizenberg, H. (2003). A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high School students. Journal of Medical Genetics, 40(e45), 1-8.

Howell, V., Haven, C., Kahnoski, K., Khoo, S., Petillo, D., Chen, J., Fleuren, G., Robinson, B., Delbridge, L., Philips, J., Marsh, D., et al (2003). HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. Journal of Medical Genetics, 40(9), 657-663.

Marsh, D., Howell, V., Benn, D., Robinson, B., Theodosopoulos, G., Riches, J., Proos, A., Eng,, C. (2001). Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography. Neoplasia (Spanish Edition): oncologia multidisciplinaria, 3, 236-244.

For more information please contact:

Phone: +61 2 99264758

Email: [email protected]

Find out more ..